Chul-Woong Chung

Company: LigaChem Biosciences Inc

Job title: Chief Technology Officer

Seminars:

11:30am Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation 11:30 am

LCB’s site-specific ConjuAllTM platform enables discrete DAR ADCs with circulation stable bioconjugation LCB’s proprietary betaglucuronidase technology enables unprecedented preclinical therapeutic indexes through tumor selective release and activation of payload Early clinical safety and efficacy across payload classes validate the LCB platformRead more

day: Day One Discovery Track